IL116882A - Monoclonal antibodies specific for different epitopes of human gp39 and methods for their use in diagnosis and therapy - Google Patents

Monoclonal antibodies specific for different epitopes of human gp39 and methods for their use in diagnosis and therapy

Info

Publication number
IL116882A
IL116882A IL11688296A IL11688296A IL116882A IL 116882 A IL116882 A IL 116882A IL 11688296 A IL11688296 A IL 11688296A IL 11688296 A IL11688296 A IL 11688296A IL 116882 A IL116882 A IL 116882A
Authority
IL
Israel
Prior art keywords
antibody
binding
protein
fragment
human
Prior art date
Application number
IL11688296A
Other languages
English (en)
Other versions
IL116882A0 (en
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL116882A0 publication Critical patent/IL116882A0/xx
Publication of IL116882A publication Critical patent/IL116882A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL11688296A 1995-01-26 1996-01-24 Monoclonal antibodies specific for different epitopes of human gp39 and methods for their use in diagnosis and therapy IL116882A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/379,057 US5876950A (en) 1995-01-26 1995-01-26 Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
PCT/US1996/001119 WO1996023071A2 (en) 1995-01-26 1996-01-26 MONOCLONAL ANTIBODIES SPECIFIC FOR DIFFERENT EPITOPES OF HUMAN gp39 AND METHODS FOR THEIR USE IN DIAGNOSIS AND THERAPY

Publications (2)

Publication Number Publication Date
IL116882A0 IL116882A0 (en) 1996-05-14
IL116882A true IL116882A (en) 2001-09-13

Family

ID=23495642

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11688296A IL116882A (en) 1995-01-26 1996-01-24 Monoclonal antibodies specific for different epitopes of human gp39 and methods for their use in diagnosis and therapy

Country Status (15)

Country Link
US (1) US5876950A (hu)
EP (2) EP1728864B1 (hu)
JP (1) JPH10513348A (hu)
AU (1) AU692074B2 (hu)
CA (1) CA2210419A1 (hu)
CZ (1) CZ233997A3 (hu)
ES (1) ES2391101T3 (hu)
FI (1) FI973120A0 (hu)
HU (1) HUP9802401A3 (hu)
IL (1) IL116882A (hu)
MX (1) MX9705610A (hu)
NO (1) NO973447L (hu)
NZ (1) NZ303375A (hu)
PL (1) PL182868B1 (hu)
WO (1) WO1996023071A2 (hu)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US7405270B2 (en) * 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
IL125928A (en) * 1996-03-20 2002-11-10 Bristol Myers Squibb Co The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations
TR199902191T2 (xx) * 1997-01-10 1999-12-21 Biogen, Inc. Anti-CD40L bile�ikleri ile lupus nefritis tedavisi
EA001426B1 (ru) * 1997-01-10 2001-02-26 Байоджен, Инк. Способы терапевтического введения анти-cd40l соединений
JP2002507967A (ja) * 1997-06-20 2002-03-12 パンゲネチックス・ベー・ファウ 疾病治療のための抗ｃｄ４０ｌイムノトキシン
EP1754490A3 (en) 1997-06-20 2010-01-20 Biogen Idec MA Inc. CD 154 blockage therapy for pancreatic islet tissue transplantation in primates
WO1999000143A1 (en) * 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
CN1173735C (zh) * 1998-04-03 2004-11-03 达特茅斯学院理事 抗-gp39抗体在狼疮及相关肾病的治疗和/或逆转中的应用
ES2246093T3 (es) * 1998-10-16 2006-02-01 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Patogenicida molecular que induce una resistencia a la enfermedad en las plantas.
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
FR2798386B1 (fr) * 1999-09-10 2003-04-25 Didier Raoult Oligonucleotides monocatenaires, sondes, amorces et procede de detection des spirochetes
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
DE19962583A1 (de) * 1999-12-23 2001-06-28 Mueller Hermelink Hans Konrad Antikörper gegen Plasmazellen
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU6158501A (en) 2000-05-12 2001-11-26 Beth Israel Hospital Compositions and methods for achieving immune suppression
SI1935427T1 (en) 2000-07-03 2018-05-31 Bristol-Myers Squibb Company USE OF HEATED CTLA4 MUTANT MOLECULES
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
ATE332309T1 (de) * 2000-08-04 2006-07-15 Ludwig Inst Cancer Res Suppressor-gen
AU2001287040A1 (en) * 2000-09-01 2002-03-13 Biogen, Inc. Methods of designing and producing novel compounds having improved binding affinity for cd154 or other trimeric proteins
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2433877C (en) * 2001-01-17 2014-11-18 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2008200400B2 (en) * 2001-01-17 2012-06-07 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
PT1397153E (pt) 2001-05-23 2008-06-12 Bristol Myers Squibb Co Métodos para proteger um transplante alogénico de ilhéus utilizando moléculas mutantes de ctla4 solúveis
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
CA2591059C (en) * 2004-12-28 2018-11-06 Innate Pharma Monoclonal antibodies against nkg2a
ATE485057T1 (de) * 2005-05-26 2010-11-15 Seattle Genetics Inc Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung
SI1912675T1 (sl) * 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
CN101500608A (zh) 2006-06-08 2009-08-05 中外制药株式会社 炎性疾病的预防或治疗药
CA2654317A1 (en) * 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
CN101484471B (zh) 2006-06-30 2013-11-06 诺沃-诺迪斯克有限公司 抗-nkg2a抗体及其用途
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR20090071652A (ko) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
HUE033325T2 (hu) * 2007-01-05 2017-11-28 Univ Zuerich Béta-ellenes amyloid kötõanyag antitestek és használatuk
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
WO2009041613A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US8846036B2 (en) * 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
CA2708065C (en) 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
ES2834741T3 (es) 2007-12-05 2021-06-18 Chugai Pharmaceutical Co Ltd Anticuerpo anti-NR10 y uso del mismo
BRPI0908508A2 (pt) * 2008-01-24 2016-03-22 Novo Nordisk As anticorpo monoclonal nkg2a anti-humano humanizado
PT2132228E (pt) * 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
EP2305300B1 (en) 2008-07-10 2016-04-06 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancer
JP2012503490A (ja) * 2008-09-26 2012-02-09 ワイス・エルエルシー 単鎖抗体ライブラリー設計
EP2367849B1 (en) 2008-12-05 2017-11-01 ALS Therapy Development Institute Method for the treatment of neurodegenerative diseases
JP5139517B2 (ja) * 2008-12-05 2013-02-06 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
TWI544077B (zh) 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
BR112013029550A2 (pt) 2011-05-17 2022-04-19 California Inst Of Techn Anticorpos neutralizantes de vírus de imunodeficiência humana e métodos de uso dos mesmos
WO2012172102A1 (en) 2011-06-17 2012-12-20 Novo Nordisk A/S Selective elimination of erosive cells
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
BR112014009069A2 (pt) 2011-10-13 2020-10-27 Bristol-Myers Squibb Company polipeptídeos de anticorpo que antagonizam cd40l
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
BR112017022101A2 (pt) 2015-04-14 2018-07-31 Chugai Seiyaku Kabushiki Kaisha composição farmacêutica para prevenção e/ou tratamento de dermatite atópica contendo antagonista de il-31 como ingrediente ativo
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC CD3 BINDING POLYPEPTIDES
EP3565596A4 (en) 2017-01-05 2020-12-16 Brown University PROCESSES AND COMPOSITIONS RELATING TO ANTI-CHI3LI ANTIBODY REAGENTS
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
US10766968B2 (en) 2017-08-23 2020-09-08 Brown University Methods and compositions relating to anti-CHI3L1 antibody reagents to treat cancer
CN108484761B (zh) * 2018-03-10 2021-04-30 吉林大学 一种特异性识别并诱导Aβ42的寡聚体及原纤维解聚的单链抗体、单链抗体基因及其应用
CN114957475B (zh) * 2018-09-26 2023-06-20 福州拓新天成生物科技有限公司 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
KR102142499B1 (ko) * 2019-09-11 2020-08-10 재단법인 오송첨단의료산업진흥재단 Ykl-40 표적 인간 단일클론항체
BR112022006590A2 (pt) 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd Preparação contendo anticorpos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
ATE188487T1 (de) * 1993-09-02 2000-01-15 Dartmouth College Anti-gp39 antikoerper und deren verwendungen
CN1137726C (zh) * 1993-09-02 2004-02-11 达特茅斯学院理事 延长体液免疫抑制的方法
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40

Also Published As

Publication number Publication date
AU4966996A (en) 1996-08-14
FI973120A (fi) 1997-07-25
WO1996023071A2 (en) 1996-08-01
HUP9802401A2 (hu) 1999-01-28
IL116882A0 (en) 1996-05-14
EP0807175A2 (en) 1997-11-19
JPH10513348A (ja) 1998-12-22
ES2391101T3 (es) 2012-11-21
AU692074B2 (en) 1998-05-28
HUP9802401A3 (en) 2003-03-28
MX9705610A (es) 1997-10-31
FI973120A0 (fi) 1997-07-25
US5876950A (en) 1999-03-02
PL323565A1 (en) 1998-04-14
PL182868B1 (pl) 2002-03-29
EP1728864B1 (en) 2012-08-01
NO973447D0 (no) 1997-07-25
NZ303375A (en) 2000-01-28
WO1996023071A3 (en) 1996-09-26
NO973447L (no) 1997-09-26
EP1728864A1 (en) 2006-12-06
CZ233997A3 (en) 1997-11-12
CA2210419A1 (en) 1996-08-01

Similar Documents

Publication Publication Date Title
US5876950A (en) Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
WO1996023071A9 (en) MONOCLONAL ANTIBODIES SPECIFIC FOR DIFFERENT EPITOPES OF HUMAN gp39 AND METHODS FOR THEIR USE IN DIAGNOSIS AND THERAPY
FI120041B (fi) Liukoisia CTLA4-molekyyleja ja niiden käyttöjä
US7105166B1 (en) Soluble CTLA4 mutant molecules and uses thereof
US5851795A (en) Soluble CTLA4 molecules and uses thereof
AU682325B2 (en) Methods for regulating the immune response using CTLA4-binding molecules and IL4-binding molecules
US5844095A (en) CTLA4 Ig fusion proteins
RU2139934C1 (ru) Гуманизированные антитела и их использование
JP3722375B2 (ja) Ｃｔｌａ４レセプター、それを含有する融合タンパク質およびそれらの使用
US6569430B1 (en) Antibodies to the antigen Campath-1
AU618989B2 (en) Improvements in or relating to antibodies
JPH08507680A (ja) 組換え抗ｖｌａ４抗体分子
NZ264003A (en) Interleukin-12 receptor protein and dna, immunoglobulin capable of binding the protein and pharmaceutical compositions
CS39092A3 (en) IgE RECEPTOR ANTIBODIES
CA2262546C (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
MXPA95001794A (en) Ctla4 molecules and il-4 link molecules and uses of mis

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees